BD and NanoString Announce Strategic Collaboration to Advance Single-Cell Spatial Multi-Omics Solutions in China
Dec 01, 2022 14:07
CST Updated
18:15
NanoString Technologies
Medical Device Provider
BD
Medical Device R&D Manufacturer, Distributor
December 1, 2022, Shanghai — Today, BD, a global leader in medical technology, and NanoString Technologies, a pioneer in global spatial biology, jointly announced the launch of a strategic collaboration in the field of single-cell spatial multi-omics. By combining their respective strengths, the partnership aims to provide one-stop technical tools and services for fundamental research, clinical studies, and biopharmaceutical development in China. This collaboration will integrate world-leading single-cell multi-omics and spatial omics technologies, focusing on future-oriented research and clinical application scenarios to create an end-to-end, full-chain solution.
Single-cell multi-omics enables researchers and clinicians to study transcriptomics, proteomics, immune repertoires, and mixed samples; while spatial omics further introduces the perspective of spatial distribution and structure. The combination of the two will reveal more details of life's complexity and can be widely applied in key areas of life and health such as oncology, immunology, virology, brain science, reproduction, dentistry, orthopedics, nephrology, intervertebral disc degeneration, and infectious diseases. It is also playing an increasingly important role in multiple fields such as botany, marine biology, and early rice panicle development.
Wang Tong, Vice President of BD Greater China Biosciences DivisionSaid: "BD Medical has the BD Rhapsody™ platform, currently the world's only platform that can truly obtain multi-omics data in the same experiment, as well as a series of solutions including analysis kits, beads, and data analysis software. We look forward to joining forces with NanoString Technologies to provide our customers with a more comprehensive, higher-dimensional, and deeper one-stop solution. Together, we will explore broader application cases and markets, contributing to fundamental research, clinical research, and pharmaceutical development in China."
Ms. Su Zhongmei, General Manager of NanoString ChinaSaid: "As a leading innovative technology company and tool solution provider in the life sciences field dedicated to scientific discovery and translational research, NanoString currently mainly offers nCounter®Fluorescent Barcode Multi-Target Expression Analysis System and GeoMx®The Digital Spatial Profiler (DSP) spatial multi-target analysis system helps researchers explore and map a comprehensive view of biology. BD's single-cell multi-omics solutions are highly complementary to NanoString Technologies, Inc.'s product portfolio. We look forward to collaborating with BD to advance researchers' work in accelerating the discovery of biomarkers and the in-depth analysis of disease mechanisms, thereby playing an increasingly important role in translational medicine and clinical applications."
The two parties will focus on the BD Rhapsody™ Single-Cell Multi-Omics and NanoString Spatial Omics products as the core integrated solution, fully leveraging the complementary advantages of their products and technologies. They will engage in comprehensive and trust-based cooperation across multiple dimensions, including market promotion and education, establishment and support of service providers, regional channel development, key account maintenance, technical solution development, and exploration of emerging application fields.